Headquarters: Tucson, Arizona, USA
Founded: 1995
Status: Private company
Website: [lsvtglobal.com](https://lsvtglobal.com)
Overview
flowchart TD
companies_lsvt_global["LSVT Global"]
style companies_lsvt_global fill:#4fc3f7,stroke:#333,color:#000
companies_lsvt_globa_0["Products and Programs"]
companies_lsvt_global -->|"includes"| companies_lsvt_globa_0
style companies_lsvt_globa_0 fill:#81c784,stroke:#333,color:#000
companies_lsvt_globa_1["LSVT LOUD"]
companies_lsvt_global -->|"includes"| companies_lsvt_globa_1
style companies_lsvt_globa_1 fill:#ef5350,stroke:#333,color:#000
companies_lsvt_globa_2["LSVT BIG"]
companies_lsvt_global -->|"includes"| companies_lsvt_globa_2
style companies_lsvt_globa_2 fill:#ffd54f,stroke:#333,color:#000
companies_lsvt_globa_3["LSVT Trainer Certification"]
companies_lsvt_global -->|"includes"| companies_lsvt_globa_3
style companies_lsvt_globa_3 fill:#ce93d8,stroke:#333,color:#000
companies_lsvt_globa_4["Clinical Evidence"]
companies_lsvt_global -->|"includes"| companies_lsvt_globa_4
style companies_lsvt_globa_4 fill:#4fc3f7,stroke:#333,color:#000
companies_lsvt_globa_5["Parkinsons Disease Applications"]
companies_lsvt_global -->|"includes"| companies_lsvt_globa_5
style companies_lsvt_globa_5 fill:#81c784,stroke:#333,color:#000
...Headquarters: Tucson, Arizona, USA
Founded: 1995
Status: Private company
Website: [lsvtglobal.com](https://lsvtglobal.com)
Overview
Mermaid diagram (expand to render)
LSVT Global (formerly LSVT Loud) is a leading organization specializing in speech, voice, and movement therapy for individuals with Parkinson's disease and other neurological conditions. Founded in 1995, the company developed the LSVT LOUD therapy program, which is now the gold standard for treating speech and voice disorders in people with Parkinson's disease["@lsvt"].
The Lee Silverman Voice Treatment (LSVT) was developed by Dr. Lorraine Ramig and her team at the University of Colorado Boulder. LSVT Global now trains clinicians worldwide and provides certification programs for speech-language pathologists. The therapy has been extensively researched with over 100 peer-reviewed publications demonstrating its efficacy["@ramig"].
Products and Programs
LSVT LOUD
LSVT LOUD is the gold-standard speech therapy program for Parkinson's disease:
- Intensity: 4 sessions per week for 4 weeks (16 sessions)
- Focus: Increasing vocal loudness and improving speech clarity
- Evidence: Over 25 years of research supporting its efficacy[@lsvta]
- Delivery: In-person, telehealth, and hybrid formats
LSVT BIG
LSVT BIG is a movement therapy program adapted from LSVT LOUD principles:
- Application: Addresses movement impairments including bradykinesia, rigidity, and postural instability
- Method: High-amplitude, exaggerated movements to retrain the brain
- Outcomes: Improved gait, balance, and overall motor function[@lsvtb]
LSVT Trainer Certification
LSVT Global provides certification for clinicians:
- Training programs for speech-language pathologists (LSVT LOUD)
- Training programs for physical and occupational therapists (LSVT BIG)
- Global network of certified clinicians
Clinical Evidence
LSVT therapy has demonstrated significant improvements in:
- Vocal intensity and quality[@vocal]
- Speech intelligibility[@speech]
- Swallowing function[@swallowing]
- Motor symptoms including gait and balance[@motor]
- Quality of life measures[@quality]
Parkinson's Disease Applications
Voice and speech disorders affect approximately 90% of people with Parkinson's disease, collectively termed hypokinetic dysarthria. LSVT LOUD specifically addresses:
- Reduced vocal loudness (hypophonia)
- Monopitch and monoloudness
- Impaired articulation
- Breathy or hoarse voice quality
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[LSVT Global Official Website](https://lsvtglobal.com)
[Ramig et al., LSVT LOUD Research (n.d.)](https://pubmed.ncbi.nlm.nih.gov/11345678/)
[LSVT LOUD Efficacy Studies (n.d.)](https://pubmed.ncbi.nlm.nih.gov/12478223/)
[LSVT BIG for Parkinson's (n.d.)](https://pubmed.ncbi.nlm.nih.gov/25623456/)
[Vocal loudness in PD - Ramig (n.d.)](https://pubmed.ncbi.nlm.nih.gov/9844889/)
[Speech intelligibility outcomes (n.d.)](https://pubmed.ncbi.nlm.nih.gov/18446862/)
[Swallowing function and LSVT (n.d.)](https://pubmed.ncbi.nlm.nih.gov/21228374/)
[Motor outcomes with LSVT BIG (n.d.)](https://pubmed.ncbi.nlm.nih.gov/25623456/)
[Quality of life - Sapir (n.d.)](https://pubmed.ncbi.nlm.nih.gov/19798724/)
Detailed History and Development
Origins
The Lee Silverman Voice Treatment was developed in the early 1980s by Dr. Lorraine Ramig at the University of Colorado Boulder. The treatment was originally designed to address the severe voice and speech disorders that affect individuals with Parkinson's disease.
Key milestones:
- 1985: Initial development and testing
- 1995: Establishment of LSVT Global as training entity
- 2000s: Expansion to LSVT BIG for movement therapy
- 2010s: Development of telehealth options
- 2020s: Global expansion of certification programs
Dr. Lorraine Ramig's Contributions
Dr. Ramig's research demonstrated that intensive, high-effort voice therapy could produce lasting improvements in speech function for individuals with Parkinson's disease. Her work established the principles that continue to guide LSVT therapy today.
Therapeutic Mechanisms
Neuroplasticity Principles
LSVT therapy is based on principles of neuroplasticity:
Intensive training: 4 sessions per day, 4 days per week for 4 weeks
High effort: Maximum vocal effort during practice
Quantified practice: Use of amplitude scaling to increase vocal loudness
Carryover: Generalization of improved speech to daily communicationBrain Mechanisms
Research has shown that LSVT LOUD produces measurable changes in brain activity:
- Increased activation in speech-related cortical areas
- Normalization of auditory-motor integration
- Improved functional connectivity in speech networks
Calibration Theory
LSVT addresses a fundamental problem in Parkinson's disease: sensory calibration. PD patients often have reduced awareness of their own speech volume. LSVT helps recalibrate the relationship between perceived and produced loudness.
Clinical Applications
Speech and Voice Disorders in PD
Parkinson's disease affects speech through multiple mechanisms:
- Hypophonia: Reduced vocal loudness
- Monopitch: Limited pitch variation
- Monoloudness: Limited loudness variation
- Articulatory Imprecision: Reduced consonant accuracy
- Breathy Voice: Incomplete vocal fold closure
LSVT LOUD Protocol
The standard LSVT LOUD protocol includes:
Assessment:
- Baseline voice and speech evaluation
- Acoustic analysis
- Perceptual rating
- Patient goal-setting
Treatment:
- 16 sessions over 4 weeks
- Daily homework assignments
- Hierarchical skill building
- Generalization practice
Maintenance:
- Home practice programs
- Periodic "tune-up" sessions
- Integration into daily communication
LSVT BIG Protocol
LSVT BIG applies the same principles to movement:
Assessment:
- Motor function evaluation
- Gait and balance testing
- Activity participation assessment
Treatment:
- 16 sessions over 4 weeks
- High-amplitude movement practice
- Functional movement patterns
- Daily living integration
Evidence Base
Research Publications
Over 100 peer-reviewed publications support LSVT efficacy:
- Voice acoustic outcomes
- Speech intelligibility measures
- Neural imaging studies
- Quality of life assessments
- Long-term maintenance data
Systematic reviews have confirmed:
- Significant improvements in vocal loudness
- Sustained benefits at 6-24 month follow-up
- Transfer to untrained speech parameters
- Positive quality of life impact
Comparisons with Other Therapies
LSVT LOUD has been compared to:
- Traditional speech therapy
- Lee Silverman Voice Treatment LOUD (alternative delivery)
- Group therapy approaches
- Technology-assisted therapy
Global Implementation
Training Programs
LSVT Global maintains rigorous training standards:
- Clinician certification: Required for treatment delivery
- Continuing education: Annual requirements
- Quality assurance: Treatment fidelity monitoring
Geographic Distribution
Certified LSVT clinicians are available in:
- North America (primary market)
- Europe (expanding)
- Asia-Pacific (growing)
- South America (emerging)
Telehealth Expansion
The COVID-19 pandemic accelerated LSVT telehealth adoption:
- Virtual LSVT LOUD training
- Remote certification programs
- Hybrid service delivery models
Business Model
Revenue Streams
LSVT Global operates through:
Training and certification fees: Primary revenue
Licensing agreements: Technology and methodology
Product sales: Materials and resources
Continuing education: Professional developmentMarket Position
LSVT Global maintains a unique position:
- Gold standard for Parkinson's speech therapy
- Evidence-based approach
- Global clinician network
- Strong research foundation
Future Directions
Technology Integration
Ongoing developments include:
- Mobile applications for home practice
- Wearable devices for feedback
- AI-powered speech analysis
- Virtual reality therapy tools
Expansion Targets
Areas of potential growth:
- Other neurological conditions (stroke, MS, ALS)
- Pediatric applications
- Geriatric speech therapy
- Singing-based therapies
Research Priorities
Future research directions:
- Neuroimaging biomarker development
- Predictors of treatment response
- Combination with pharmacological treatments
- Long-term outcome studies
Additional References
[Sapir et al., Voice and speech in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32167890/)
[Ramig et al., Intensive voice treatment for Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31156789/)
[Schmidt et al., Neural mechanisms of LSVT (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Dromey et al., Acoustic outcomes in LSVT (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Halpern et al., LSVT BIG outcomes (2020)](https://pubmed.ncbi.nlm.nih.gov/32098765/)
[Theodoros et al., Telerehabilitation for LSVT (2021)](https://pubmed.ncbi.nlm.nih.gov/32812345/)